2025
Risk of Atherosclerotic Cardiovascular Disease After Chronic Obstructive Pulmonary Disease Hospitalization among Primary and Secondary Prevention Older Adults
Mosher C, Osazuwa‐Peters O, Nanna M, MacIntyre N, Que L, Palmer S, Jones W, O'Brien E. Risk of Atherosclerotic Cardiovascular Disease After Chronic Obstructive Pulmonary Disease Hospitalization among Primary and Secondary Prevention Older Adults. Journal Of The American Heart Association 2025, 14: e035010. PMID: 39791395, PMCID: PMC12054414, DOI: 10.1161/jaha.124.035010.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary disease hospitalizationsChronic obstructive pulmonary diseaseAtherosclerotic cardiovascular diseaseSecondary prevention cohortPrevention cohortASCVD hospitalizationRisk of atherosclerotic cardiovascular diseaseHazard ratioHospital outcomesHigh riskRisk factorsCardiovascular disease eventsCardiovascular diseasePrimary prevention cohortIdentified multiple risk factorsRisk of cardiovascular disease eventsMultiple risk factorsPulmonary disease hospitalizationsObstructive pulmonary diseaseOlder adultsHigh-risk patient cohortASCVD eventsDisease eventsHigh-risk patientsMeta-analyses
2017
Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction
Feher A, Kampaktsis PN, Parameswaran R, Stein EM, Steingart R, Gupta D. Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction. The Oncologist 2017, 22: 213-221. PMID: 28159866, PMCID: PMC5330698, DOI: 10.1634/theoncologist.2016-0110.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionThrombocytopenic cancer patientsSevere thrombocytopeniaMajor bleedingHematologic malignanciesImproved survivalMyocardial infarctionAspirin useCancer patientsPatient cohortDays of AMIGuideline-recommended medical therapyMemorial Sloan-Kettering Cancer CenterHigh-risk patient cohortTreatment of AMIBenefits of aspirinFatal bleeding eventsOverall patient cohortAspirin therapyBleeding eventsSTP patientsThienopyridine treatmentMedical therapyPlatelet countCancer CenterColorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions
Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, Coussens LM, Gast CE, Geltzeiler CB, Hansen L, Kelley KA, Lopez CD, Rana SR, Ruhl R, Tsikitis VL, Vaccaro GM, Wong MH, Mayo SC. Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions. Cellular And Molecular Gastroenterology And Hepatology 2017, 3: 163-173. PMID: 28275683, PMCID: PMC5331831, DOI: 10.1016/j.jcmgh.2017.01.006.Peer-Reviewed Original ResearchColorectal cancerHigh-risk patient cohortEarly detectionEffective prognostic indicatorTreatment of patientsTumor immune therapyNew therapeutic regimensColorectal tumor biologyCurative resectionIntrahepatic recurrenceRecurrent diseaseSystemic therapyTreatment toxicityLiver metastasesImmune therapyTreatment regimensPrognostic indicatorTherapeutic regimensCancer carePatient cohortMetastatic spreadTreatment responseHigh riskPrognostic studiesPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply